Highest-materiality recent filing
MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS
Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026
Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.
MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026
Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.
MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded
Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.
Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.
MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform
Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.
MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023
Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.
MiNK Therapeutics stockholders approve 1-for-10 reverse stock split effective Jan 28
Special meeting held Jan 17, 2025; 27,582,512 shares voted (quorum).
MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M
Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.
MiNK appoints former HHS ASPR Robert Kadlec to board
Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.
MiNK Therapeutics receives Nasdaq delisting notice for failing to meet $1.00 bid price rule
Nasdaq notified MiNK on Aug 27, 2024 that it failed to regain compliance with the $1.00 minimum bid price within the 180-day grace period ending Aug 26, 2024.
MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance
Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.
MiNK Therapeutics raises ~$5.8M via 4.64M shares at $1.25/share, 25% premium to VWAP
Issued 4,640,000 common shares at $1.25 per share, a 25% premium to 30-day VWAP.
MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end
Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.
On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.
Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.
Max materiality 0.85 · Median 0.60 · Most common event earnings